Background. Invasive candidiasis (IC) is an important healthcare-related infection, with increasing incidence and a crude mortality exceeding 50%. Numerous treatment options are available yet comparative studies have not identified optimal therapy.
Epidemiologic studies from the last 2 decades have identified Candida species as the fourth most common cause of nosocomial bloodstream infection [1] [2] [3] [4] . Despite recognition of disease risk factors and advances in infection prevention, candidemia-related hospitalizations and mortality have continued to rise [1, 5] . Mortality rates associated with invasive candidiasis (IC) approach 50% [6] [7] [8] [9] [10] [11] [12] [13] . Moreover, longitudinal studies have detected a global shift in epidemiology toward non-albicans Candida species, particularly Candida glabrata [14] [15] [16] [17] [18] [19] [20] [21] [22] . The changing epidemiology of Candida bloodstream infection is of concern, because these species exhibit variable susceptibility to antifungal drugs with some of these emerging species [13, [23] [24] [25] [26] .
The number of antifungal drugs for IC has increased during the last 2 decades [27] [28] [29] [30] [31] [32] . Several large randomized trials have compared these antifungal drug therapies for this disease state. However, these studies, powered for noninferiority, have not identified an optimal treatment strategy. The goal of the present study was to analyze individual patient data from these trials to determine mortality and clinical cure in patients with candidemia and other forms of IC across treatment regimens. We hypothesized that the increased sample size of a pooled analysis of patient-level data would allow detection of differences in patient outcomes.
METHODS

Inclusion Criteria
We identified randomized clinical trials that compared antifungal treatments for candidemia and IC. Criteria for trial selection included the availability of data on mortality and clinical success with each Candida species. As our focus was on the use of individual patient-level data, we considered only studies in which individual patient data were available [33] . We searched multiple databases (10/1010, repeated 1 January 2011, and 1 June 2011) using the terms ''candidemia,'' ''invasive candidiasis,'' ''antifungal,'' and the names of each specific antifungal drug. Trials of biologic agents were excluded.
Outcomes
The primary outcome was 30-day all-cause mortality. The secondary outcome was clinical and microbiologic success, defined as symptom resolution and negative cultures at the end of therapy (typically 14 days). The rationale for these measures includes consistency of definition and data availability across trials.
Host-, Organism-, Disease-, and Treatment-Related Data
The rationale for choice of factors was based on prior association with outcome [2, 6, [34] [35] [36] [37] . Demographics included sex and age. Information was collected on comorbid conditions, including malignancy, organ transplantation, and surgery within 30 days of infection, renal (creatinine level .3.0 mg/dL or hemodialysis) or hepatic dysfunction (laboratory values .5 times the upper limit of normal), neutropenia within 30 days of infection, use of parenteral nutrition at the time of infection, immunosuppressive therapy (corticosteroids or chemotherapy) at diagnosis, antibiotics within 30 days of infection, the presence of a central venous catheter (CVC) at the time of enrollment, the need for mechanical ventilation, and intensive care unit stay at diagnosis. Infection and organism factors included the site of infection, Candida species, and a measure of severity of illness, the Acute Physiology and Chronic Health Evaluation (APACHE) II score. Data from cases with missing fungal species information and multiple Candida species were excluded from analysis. The treatment variables evaluated included specific antifungal therapy and removal of CVCs at any time during the treatment phase. Data from combination antifungal therapy were excluded. Information regarding the timing of start of therapy relative to disease diagnosis and the timing of CVC removal were not available for all patients.
Data Source and Management
The data from the modified intent-to-treat patient populations were provided by the industry sponsor or principal investigator. The similarity of the trials, including design, disease, and host factor definitions; treatment initiation and duration strategy; and the availability of identical outcome data based on both definition and timing (Table 1) provided a strong rationale to pool individual patient-level data. Data extraction and transformation process involved 2 core stages: preprocessing stage and the data integration stage. Preprocessing involved the extraction of raw laboratory files and conversion into SAS software (version 9.1.3; SAS Institute) data sets. A set of programs were developed to assess and validate the content quality of the source data (eg, missing values, frequency, and format consistency). In the data integration stage, each cleaned source file was transformed and restructured into a SAS data set with standardized naming conventions and value formats used in the study.
Data Analysis
Frequencies of each Candida spp, host, and treatment variable were determined. Missing data were treated as missing. Antifungal therapy was considered at the level of the individual drug and drug class. 
RESULTS
Description of Studies
Nine randomized trials met the inclusion criteria. Patientlevel data were available for 7 studies (Table 1) . One trial was excluded due to inclusion of a biologic agent [38] . Data from 1 trial were not available despite attempts to contact the authors and industry sponsors [39] . The majority of trials served as US Food and Drug Administration or European Medicines Agency licensing studies. Antifungal regimens included 2 polyenes, 2 triazoles, and 3 echinocandins. One trial included combination therapy and this arm was excluded from analysis by our a priori inclusion criteria.
Host-, Organism-, and Treatment-Related Variables
The analysis included 1915 patients with IC for the mortality end point (1895 for the composite success end point). The frequency of disease, host, and organism variables in the data set are presented in Table 2 . The mean patient age was 55.1 year, and 57.5% of the patients were men. C. albicans was the most frequent Candida species (n 5 837; 43.7% of cases), followed by C. tropicalis (n 5 352; 18.3%), C. parapsilosis (n 5 299; 15.6%), C. glabrata (n 5 206; 10.7%), and C. krusei (n 5 40; 2.0%). The mean APACHE II score was 14.9. The majority of patients (n 5 1492; 78%) had a CVC in place at enrollment.
Factors Associated With Mortality and Treatment Response
The overall 30-day mortality was 31.4%, and composite treatment success at the end of treatment was 67.4%. Univariate analyses identified multiple factors significantly associated with mortality and treatment success (Table 3) . Demographic, disease, and host factors associated with higher risk of death in the entire cohort included increasing APACHE II score, advancing age, the presence of malignancy, neutropenia, immunosuppressive therapy, total parenteral nutrition (TPN), mechanical ventilation, and renal and hepatic dysfunction. Among the infecting Candida species, C. tropicalis was associated with higher mortality (C. tropicalis 41% vs other species 29%; P , .0001). Conversely, C. parapsilosis infection was associated with lower mortality than non-parapsilosis infection (C. parapsilosis 22.7 % vs other species 33.0%; P , .001). A comparison of patient, disease, treatment, and outcome variables across individual Candida species demonstrated higher APACHE II scores and more frequent neutropenia in the C. tropicalis subgroup (APACHE II in the Unless otherwise specified data represent number of patients and percentage with the variable among those in the outcome category. Missing data for each variable can be determined by adding the number in each outcome category and subtracting from the total number of patients with outcomes for mortality (n 5 1915) and success (n 5 1895). a v 2 test comparing across categories.
C. tropicalis subgroup, 16.4 6 7.6 vs 14.6 6 7.1 among other species; P 5 .001 and neutropenia in the C. tropicalis subgroup, 14% vs 6% among other species; P , .0001). Conversely, the APACHE II scores were lower for the C. parapsilosis subgroup compared with other species (12.8 6 6.6 vs 15.4 6 7.3; P , .0001). With respect to antifungal regimens, patients randomized to receive an echinocandin had significantly better survival rates than those who received either a polyene or a triazole (mortality, 27% for echinocandins vs 36% for other regimens [P , .0001], 36% for triazoles vs 30% for other drugs [P 5 .006], and 35% for polyenes vs 30% for other drugs [P 5 .04]).
Survival was significantly better for those who underwent CVC removal during the treatment phase (mortality for CVC removal, 28% vs 41% for CVC retention; P , .0001). Analysis of these variables using composite success instead of mortality as the treatment end point revealed very similar associations (Table 3) . In subgroup analysis, the impact of the same host-, organism-, and treatment-related variables remained statistically similar for the entire non-albicans Candida population as well as individual species, including C. albicans, C. tropicalis, and C. glabrata.
Logistic regression analysis for the aggregate data set identified increasing age (odds ratio [OR], 1.01; 95% confidence interval [CI], 1.00-1.02; P 5 .02), greater APACHE II score (OR, 1.11; 95% CI, 1.08-1.14; P 5 .0001), use of immunosuppressive therapy (OR, 1.69; 95% CI, 1.18-2.44; P 5 .001), and infection with C. tropicalis (OR, 1.64; 95% CI, 1.11-2.39; P 5 .01) as associated with greater mortality (Table 4) . Conversely, removal of CVC at any time during treatment (OR, 0.50; 95% CI, .35-.72; P 5 .0001) and echinocandin treatment (OR, 0.65; 95% CI, .45-.94; P 5 .02) were associated with reduced mortality. A similar model was demonstrated for the C. albicans cohort. For the non-albicans Candida subgroup, only echinocandin treatment, CVC removal, and APACHE II scores remained independently associated with the mortality. For the C. glabrata subgroup, CVC removal continued to influence outcome. However, for C. tropicalis and C. parapsilosis, only disease severity predicted survival. Examination of the data for a study effect by inclusion of trial number into the final model did not affect analyses outcome.
Similar multivariable models were explored for the secondary composite success end point. Echinocandin therapy remained associated with increased response for the entire cohort, and for the C. albicans and C. glabrata groups. CVC removal also favorably affected response for the entire population, the non-albicans Candida group and for C. tropicalis. APACHE II scores also remained a strong predictor of response in each of these models. Additional subgroup multivariate analyses for patients with candidemia were concordant with the aggregate results. Specifically, the use of an echinocandin (OR, 0.50; 95% CI, .35-.72; P 5 .0001) and CVC removal (OR, 0.45; 95% CI, .31-.67; P 5 .0001) remained similarly protective from death.
In a sensitivity analysis, we explored whether the impact of CVC removal and antifungal drug class on outcomes was affected by other variables. We repeated multivariable analyses incorporating interaction terms between CVC removal or antifungal drug class and each of the relevant variables (based on significance in univariate analysis). We also calculated and compared the frequency of each variable's statistical significance in univariate analyses in patients with or without CVC removal and for each drug class. Furthermore, we examined the impact of CVC removal and drug class in a number of APACHE II cohorts. The impact of CVC removal was similar and significant for the lowest 3 APACHE II quartiles (Figure 1 ). For the highest APACHE II quartile (.34), CVC removal was not associated with improved outcome. Receipt of an echinocandin antifungal was associated with a favorable outcome in the first 2 APACHE II quartiles. For the higher quartiles (.24), drug class did not affect outcome. Incorporation of interaction terms in the multivariate models did not affect the value of either CVC removal or echinocandin therapy (data not shown).
COMMENT IC is largely a disease of medical progress and its incidence parallels the progress in healthcare technology [2, 37, [40] [41] [42] . Despite advances in drug development [41, [43] [44] [45] [46] [47] [48] ] the incidence and mortality associated with IC have not changed substantially in the last 2 decades [12, 13] . Thus, a great deal of investigation and the goal of the current study has centered on identification of treatment factors to improve management of IC. Previous retrospective analyses have demonstrated that early administration of antifungal drug and removal of CVCs in candidemia improve outcome [34, 42, [50] [51] [52] [53] [54] [55] [56] .
Our analysis identified 2 modifiable management strategies to improve patient outcomes. The first was the identification of optimal antifungal therapy. Use of an echinocandin was associated with reduced mortality compared with use of a drug from either the triazole or polyene classes. Comparative trials designed to assess superiority of one antifungal class over another for treatment of IC are unavailable and barring development of new antifungals, are unlikely to be undertaken in the future. Study level meta-analyses have corroborated the findings of the individual trials but have not yielded additional knowledge. [57, 58] . For example, they identified significantly greater toxicity associated with amphotericin B than triazole or echinocandin therapy but, not any differences in efficacy. The pooled analysis of individual patient-level data may, however, discern the impact of treatment strategies and take into account potentially confounding influences, such as host-and organism-related factors [59] . From this quantitative review, we identified that echinocandin therapy was associated with reduced mortality. These findings support recent treatment guidelines that recommend an echinocandin as a first-line choice for IC [44] , particularly for the critically ill, those with prior triazole exposure, and those infected with less susceptible Candida spp such as C. glabrata and C. krusei. Our results support an expansion of these first-line recommendations to most patients with IC and candidemia. Notably, the superiority of the echinocandin class was evident among patients with a wide range of severity of illness (up to an APACHE II score of 24) and for both C. albicans and non-albicans groups. The species for which an echinocandin appeared least effective in univariate analysis was C. parapsilosis. This previously described observation is not surprising, given the higher minimum inhibitory concentrations of echinocandins with C. parapsilosis. However, that higher mortality has not been definitively demonstrated for C. parapsilosis when treated with an echinocandin in these trials, which in the current analysis may be explainable by the organisms's relatively lower virulence [18, 42, 44] .
The second observation from our analyses involves management of CVCs. Numerous studies have identified intravascular catheters as a risk factor for candidemia. Catheters, like other medical devices, can serve as a substrate for Candida biofilm infection, which exhibits a drug-resistant phenotype [60, 61] , necessitating biofilm extirpation for treatment success [62, 63] . Retrospective analyses, with their inherent limitations, have demonstrated that CVC removal can shorten the duration of candidemia and enhance the likelihood of survival. Many investigations have been unable to control for other disease variables, most importantly severity of illness (eg, APACHE II). In several of the studies in which CVC removal was found to improve outcome, APACHE II scores were higher in the cohort for which the devices were retained [11, 55, [64] [65] [66] , perhaps because of the critical need of CVCs for therapy or the hesitancy of clinicians to expose some patients to the risk associated with device replacement. In addition, a recent analysis demonstrated that early CVC removal did not influence outcome [66] . Despite the limitations of available studies, consensus guidelines support removal of vascular catheters, when feasible, in nonneutropenic patients with candidemia [44, 52] . In the current investigation CVC removal was not randomized and specific data regarding the exact timing of CVC removal were not available for all patients. Therefore, we could not explore the impact of early CVC removal on the outcome. However, our analysis does attempt to account for other patient and disease variables that affect patient outcome in IC. We did not identify a preponderance of these factors in either the CVC removal or CVC retention cohorts. Furthermore, interaction analyses in multivariable modeling were not statistically significant. Interestingly, in analysis of the impact of severity of illness, we identified an APACHE II group for which CVC removal was not helpful. However, for patients with scores in this range (.30), very few treatments of any type rescue patients from death. In the absence of a randomized trial of early CVC removal versus retention, it is likely this component of management will remain controversial.
Several limitations in our analysis merit mention. First, these trials often exclude patients who fall into the extremes of the clinical spectrum, such as those who are ambulatory and only mildly ill and those who are immunocompromised and/or severely ill. Tangible evidence of this difference is clear in comparison of APACHE II scores and mortality rates in retrospective and randomized treatment trials. Thus, caution must be exercised in extrapolation of the observations for all patients. Second, there are important, management and outcome questions that we are unable to address. For example, the trials excluded or provided limited information in several populations for which IC is important, including neonates and patients with neutropenia. In addition, the data are insufficient to address critical issues regarding prior antifungal therapy, the specific timing of antifungal administration, and CVC removal relative to IC diagnosis. Available data permitted only assessment of all-cause mortality and not that attributable to IC or other outcomes of importance, such as duration of candidemia and relapse. Furthermore, because these studies were undertaken during a 15-year period, the standard of care may have changed. However, the APACHE II scores and overall mortality throughout the study period were remarkably similar.
These limitations notwithstanding, the strengths of these observations warrant consideration. This is the largest patientlevel quantitative review undertaken for this important and emerging infectious disease. The results extend those of previous investigations including the identification of numerous host and disease state variables that affect the outcome of IC. However, host and disease state factors are often immutable. The most important finding from the current study is demonstration of 2 management strategies that were associated with improved survival (.10%). First, the findings lend support for the hypothesis that CVC retention has a negative impact on outcome in patients with candidemia. The second observation identified a choice of an antifungal from the echinocandin drug class as optimal for patient survival and patient success. In contrast to the current guidelines, the findings of our analysis suggest that this drug choice should be considered as initial therapy for most patient groups and not only those with severe illness, immunocompromised status, or suspected infection with a non-albicans Candida species.
Notes
